218 related articles for article (PubMed ID: 23338972)
1. NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.
Zhu H; Vishwamitra D; Curry CV; Manshouri R; Diao L; Khan A; Amin HM
J Pathol; 2013 May; 230(1):82-94. PubMed ID: 23338972
[TBL] [Abstract][Full Text] [Related]
2. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.
Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM
Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514
[TBL] [Abstract][Full Text] [Related]
3. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
5. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198
[TBL] [Abstract][Full Text] [Related]
7. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
[TBL] [Abstract][Full Text] [Related]
8. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.
Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651
[TBL] [Abstract][Full Text] [Related]
9. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA
Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525
[TBL] [Abstract][Full Text] [Related]
11. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.
Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA
J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456
[TBL] [Abstract][Full Text] [Related]
12. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.
Vishwamitra D; Curry CV; Shi P; Alkan S; Amin HM
Neoplasia; 2015 Sep; 17(9):742-754. PubMed ID: 26476082
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
[TBL] [Abstract][Full Text] [Related]
15. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.
Zhang Q; Wang HY; Liu X; Bhutani G; Kantekure K; Wasik M
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11977-82. PubMed ID: 21715655
[TBL] [Abstract][Full Text] [Related]
16. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
17. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.
Shi B; Vishwamitra D; Granda JG; Whitton T; Shi P; Amin HM
Neoplasia; 2013 Jun; 15(6):669-83. PubMed ID: 23730215
[TBL] [Abstract][Full Text] [Related]
18. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
